Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Top-down infliximab versus step-up therapy in children with Crohn's disease
NL-OMON52984Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Clinical remission at 52 weeks without additional Crohn's disease-related therapy or surgery. Started Apr 2015; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON52984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52984.